Telomir Pharmaceuticals, Inc.
TELO Nasdaq Pharmaceutical Preparations Financials FY2022–FY2025
Last close · Oct 23, 2026
$0.98
3.5%What Telomir Pharmaceuticals, Inc. does
No business description yet.
- Legal name
- Telomir Pharmaceuticals, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Accession · CIK
- 0001493152-26-010625
0001971532
Revenue and margins
Telomir Pharmaceuticals, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Telomir Pharmaceuticals, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 7.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably Telomir Pharmaceuticals, Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.0M | $0.0M | $1.3M | $7.3M |
| Current ratio | 0.0x | 0.3x | 1.9x | 5.1x |
| Quick ratio | 0.0x | 0.3x | 1.9x | 5.1x |
| Total assets | $0.0M | $4.8M | $1.3M | $7.3M |
| Total liabilities | $1.0M | $1.3M | $0.7M | $1.4M |
| Shareholders' equity | −$0.9M | $3.4M | $0.6M | $5.9M |
| Net debt (− = net cash) | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — |
| Current ratio rose | — | ✓ | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | ✕ |
| Gross margin rose | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 | — / 6 |
| Accruals ratio | −791.4% | −382.0% | −375.9% | −155.2% |
| Altman Z'' | — | — | — | — |
4 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | $0.8M | $1.6M | $2.2M | $2.4M |
| Interest expense | — | $1.6M | $4.3M | — |
| Net income | −$0.9M | −$13.1M | −$16.5M | −$10.4M |
| Diluted EPS | −$0.03 | $0.48 | −$0.56 | −$0.33 |
| Diluted shares | 0.03B | 0.03B | 0.03B | 0.03B |
| Cash flow | ||||
| Cash from operations | −$0.5M | −$3.9M | −$5.1M | −$3.7M |
| Stock-based compensation | — | — | $6.9M | $5.3M |
| Balance sheet | ||||
| Cash and short-term investments | $0.0M | $0.0M | $1.3M | $7.3M |
| Current assets | $0.0M | $0.4M | $1.3M | $7.3M |
| Current liabilities | $1.0M | $1.3M | $0.7M | $1.4M |
| Total assets | $0.0M | $4.8M | $1.3M | $7.3M |
| Total liabilities | $1.0M | $1.3M | $0.7M | $1.4M |
| Shareholders' equity | −$0.9M | $3.4M | $0.6M | $5.9M |
| Returns | ||||
| Return on equity | — | −1,045.4% | −810.2% | −317.6% |
| Return on assets | −1,753.8% | −542.1% | −542.3% | −240.3% |
| Return on tangible equity | — | −380.2% | −2,571.2% | −176.1% |
| Growth | ||||
| EPS growth | — | — | −216.7% | — |
| Share count change | — | 1.8% | 8.2% | 7.2% |
| Financial health | ||||
| Current ratio | 0.0x | 0.3x | 1.9x | 5.1x |
| Quick ratio | 0.0x | 0.3x | 1.9x | 5.1x |
| Quality scores | ||||
| Accruals ratio | −791.4% | −382.0% | −375.9% | −155.2% |
Source: SEC EDGAR XBRL filings (CIK 0001971532). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.